Cargando…
Effect of Clemastine on Neurophysiological Outcomes in an Ovine Model of Neonatal Hypoxic-Ischemic Encephalopathy
Originally approved by the U.S. Food and Drug Administration (FDA) for its antihistamine properties, clemastine can also promote white matter integrity and has shown promise in the treatment of demyelinating diseases such as multiple sclerosis. Here, we conducted an in-depth analysis of the feasibil...
Autores principales: | Mike, Jana Krystofova, White, Yasmine, Hutchings, Rachel S., Vento, Christian, Ha, Janica, Iranmahboub, Ariana, Manzoor, Hadiya, Gunewardena, Anya, Cheah, Cheryl, Wang, Aijun, Goudy, Brian D., Lakshminrusimha, Satyan, Long-Boyle, Janel, Fineman, Jeffrey R., Ferriero, Donna M., Maltepe, Emin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10670092/ https://www.ncbi.nlm.nih.gov/pubmed/38002819 http://dx.doi.org/10.3390/children10111728 |
Ejemplares similares
-
Perinatal Azithromycin Provides Limited Neuroprotection in an Ovine Model of Neonatal Hypoxic-Ischemic Encephalopathy
por: Mike, Jana Krystofova, et al.
Publicado: (2023) -
Clemastine Induces an Impairment in Developmental Myelination
por: Palma, Ana, et al.
Publicado: (2022) -
Insights on therapeutic potential of clemastine in neurological disorders
por: Jiang, Sufang, et al.
Publicado: (2023) -
Repurposing Clemastine to Target Glioblastoma Cell Stemness
por: Sun, Michael A., et al.
Publicado: (2023) -
Mechanical forces alter endothelin-1 signaling: comparative ovine models of congenital heart disease
por: Zhu, Terry, et al.
Publicado: (2020)